Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms... Show more
a company, which engages in researching and developing biotechnology
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| EHSTX | 31.46 | 0.21 | +0.67% |
| Eaton Vance Large-Cap Value A | |||
| LAMAX | 26.94 | 0.13 | +0.48% |
| Lord Abbett Dividend Growth A | |||
| SIVIX | 16.88 | 0.06 | +0.36% |
| State Street Instl Small-Cap Equity Inv | |||
| FTHMX | 33.19 | 0.08 | +0.24% |
| FullerThaler Behav Md-Cp Eq Inst | |||
| WSHCX | 66.43 | -0.02 | -0.03% |
| American Funds Washington Mutual C | |||
A.I.dvisor indicates that over the last year, INBX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if INBX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To INBX | 1D Price Change % | ||
|---|---|---|---|---|
| INBX | 100% | -3.16% | ||
| AXON - INBX | 48% Loosely correlated | +0.47% | ||
| SNTI - INBX | 39% Loosely correlated | -5.52% | ||
| VCYT - INBX | 37% Loosely correlated | -22.52% | ||
| SGMT - INBX | 37% Loosely correlated | -2.74% | ||
| ARRY - INBX | 37% Loosely correlated | +2.76% | ||
More | ||||
INBX saw its Momentum Indicator move below the 0 level on July 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for INBX turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INBX broke above its upper Bollinger Band on July 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INBX's RSI Indicator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where INBX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 185 cases where INBX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: INBX's P/B Ratio (212.766) is slightly higher than the industry average of (19.620). P/E Ratio (0.198) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.